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2Abstract
Purpose of review: The structural damage caused by rheumatoid arthritis (RA) can often be mitigated by
orthopaedic surgery in late disease. This study evaluates the value of predictive factors for orthopaedic intervention.
Methods: A systematic review of literature was undertaken to identify papers describing predictive factors for
orthopaedic surgery in RA. Manuscripts were selected if they met inclusion criteria of cohort study design, diagnosis
of RA, follow-up duration/disease duration ≥3 years, any orthopaedic surgical interventions recorded, and then 
summarised for predictive factors. A separate predictive analysis was performed on two consecutive UK Early RA
cohorts, linked to national datasets.
Recent findings: The literature search identified 15 reports examining predictive factors for orthopaedic
intervention, 4 inception, 5 prospective and 6 retrospective. Despite considerable variation, acute phase, x-ray
scores, women and genotyping were the most commonly reported prognostic markers. The current predictive
analysis included 1602 procedures performed in 711 patients (25-year cumulative incidence 26%). Earlier
recruitment year, erosions and lower haemoglobin predicted both intermediate and major surgery (P<0.05).
Summary: Studies report variations in type of, and predictive power of clinical and laboratory parameters for
different surgical interventions suggesting specific contributions from different pathological and/or patient-level
factors. Our current analysis suggests that attention to non-inflammatory factors in addition to suppression of
inflammation are needed to minimise the burden of orthopaedic surgery.
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INTRODUCTION
3Physicians rely on markers of disease severity for making management decisions in RA. Many studies have
examined risk factors for joint damage as measured on radiographs, and standard measures of active disease have
featured in most of these [1,2,3] There are fewer reports on structural damage as measured by need for orthopaedic
surgery, mainly because such studies require long follow-up and large sample sizes, previously difficult to achieve
in inception cohort studies.[4,5]
Several factors other than joint pathology contribute to decisions to undergo surgery, including patient choice,
severity of reported pain, comorbidities, accessibility of health resources and orthopaedic surgery. Clinicians would
benefit from reliable predictors of subsequent joint surgery in RA, and whether these differ from radiological joint
damage, in order to identify reversible risk factors for treatment strategies and to prioritise research in these patients.
The objectives of this study were i) to explore prognostic factors for orthopaedic intervention in RA reported in the
literature ii) to identify the most powerful combination of predictive factors for orthopaedic surgery over 25 years
in two large ongoing prospective observational studies from the UK.
METHODS
Systematic review.
A systematic review protocol was developed to ensure that objectives and aims where clearly outlined from outset
and submitted and approved by PROSPERO. Publications describing predictive factors for orthopaedic surgery in
patients with RA were identified by computerised searches of Medline, PubMed, Cochrane Library (incl
CENTRAL, CDSR, DARE, HTA) and Scopus supplemented by lateral search techniques: checking reference
lists, key word searches in Google Scholar and ‘cited by’ option in PubMed. In addition, lateral search
techniques, such as checking reference lists, performing key word searches in Google Scholar and using the ‘cited
by’ option in PubMed, were used. All databases were searched from January 1st 1975 to February 31st 2015. The
search strategy used a mixture of key words and MeSH terms on the title/abstract and full text as appropriate.
The following keywords and combinations were used: (([exp Arthritis, Rheumatoid/] AND ([orthopaedic surgical
procedures OR orthopaedic procedures OR orthopaedic interventions OR orthopaedic surgery OR [joint
replacement.mp)) OR [hip replacement.mp)) OR [knee replacement.mp)) OR hand surgery OR wrist surgery OR
foot surgery OR prosthetic replacement OR prostheses AND predictive factors OR prognostic factors OR risk
factors NOT ([exp Arthritis, Juvenile Rheumatoid/] OR [JIA.mp]) NOT ([clinical trial, phase i/ OR clinical trial,
phase ii/ OR clinical trial, phase iii/ OR clinical trial, phase iv/ OR controlled clinical trial/ OR randomized
controlled trial/] OR [exp case reports/] OR [randomized clinical trial.mp]). Limit to year=”1980-2015” and English
language.
Manuscripts were selected for review if they met the following inclusion criteria: Prospective or retrospective cohort
study design, physician or ARA or ACR or EULAR diagnosis of RA, follow-up duration/disease duration ≥3 years, 
predictive factors for any orthopaedic surgical interventions recorded.
4UK RA orthopaedic datasets
We used two well described multi-centre UK inception cohorts of RA patients recruited prior to DMARD use, the
Early RA Study (ERAS, 9 rheumatology centres in England between 1986-1999) and the Early RA Network
(ERAN, 23 in England, Wales and Ireland from 2002-2010).[6] Numbers and median follow up was 1465 and
10years (maximum 25years), and 1236 and 6years (maximum 10years) respectively. Time to first DMARD
following baseline assessment was 2 and 1 month. Median time from symptom-onset to first visit was 6 months in
each cohort.
These consecutive cohorts had very similar design and modes of data collection allowing combined analysis. In
view of reports of greater predictive value of first year variables [5,7] both baseline and first year standard
parameters have been included. [6] All centres followed the framework of published UK guidelines for management
of RA, which included mainly sequential DMARDs in ERAS, standard UK practice for early RA in the
1980s/90s.[6] ‘Step-up/add-on’ combination therapies were initially reserved for more severe RA only, but
gradually became more common.[8] In ERAN, more frequent earlier use of combination DMARDs and biologics
were employed in line with contemporary UK guidelines.[9]
Data linkage to national sources was performed through unique NHS number and included Hospital Episode
Statistics (HES), which provides information on all National Health Service (NHS) orthopaedic interventions in
England, and the National Joint Registry (NJR) which contains information on hip, knee and ankle joint replacement
surgery across both the NHS and independent healthcare sectors, as previously documented in greater detail.[6]
Orthopaedic interventions undertaken after the diagnosis of RA were categorised by joint type and procedure as
previously described.[5,6] Major: primary or secondary large joint replacement surgery. Intermediate: wrist, hand,
hind/fore-foot joint reconstructive procedures (excision arthroplasty, synovectomy, arthrodesis). Minor: soft tissue
procedures (e.g. tendon surgery). Minor procedures are omitted from this report due to their wide heterogeneity
and lack of statistically significant findings from predictive analysis.
Statistical analysis
Survival analysis was used to examine predictive values of variables for time to first orthopaedic intervention. Cox
regression, the most widely used method of survival analysis, can produce biased effect estimates in the presence
of competing risks, such as death, using non-informative censoring methods. Because of the large number of deaths
over the 25year study period, competing-risks regression was used, which accounts for patient follow-up, with the
event defined as first orthopaedic intervention and competing-risk defined as death. Patients who did not experience
either of these events were censored at end of 2011. Separate models were estimated for intermediate and major
surgery, total hip (THR) and knee replacement (TKR). The models employed absolute values of variables, first at
baseline then at 1-year.
The following were entered into the model as core covariates of interest, given their importance in RA: gender, age
at disease-onset, recruitment year, time to diagnosis at baseline, rheumatoid factor (RF), BMI, HAQ, disease activity
score (DAS) based on the original DAS (ERAS) and modified DAS28 (ERAN),[10] and its individual components
5including tender (TJC) and swollen joint counts (SJC), patient-reported visual analogue scale (VAS), haemoglobin,
ESR, hands and feet x-rays assessed for erosions by each centre (Larsen scores were available in a subgroup of 70%
of ERAS patients as previously described).[3] As baseline and 1-year variables did not differ significantly in these
patients (data not shown), sub group analysis included Larsen scores.
In order to establish other covariates to include in the model, univariate analysis was undertaken (results not shown).
Those significant to p<0.01 were also included. In further models, DAS and the proportion of DAS attributable to
patient-reported components (TJC and VAS) termed DAS-P were also examined.[11] DAS and DAS-P were only
weakly correlated (r<0.50), so were included together. Overall missing baseline data were infrequent (around 5%),
unlikely to introduce bias. Sensitivity analysis was performed to test robustness of multivariate models by excluding
variables with missing data both separately and together in the models (see supplementary material). To assess
variance and predictive strength of the regression models, the pseudo R2 and Area Under the Curve (AUC) were
examined for baseline and 1-year models. Those variables with 10 year follow-up were entered as time-varying
covariates (TVC), where missing data were imputed using multiple imputation techniques to test the assumption of
proportionality over time. Finally, to investigate predictors of multiple surgeries, negative binomial regression was
used on the total major or intermediate interventions. All analysis was conducted using Stata (version 13) with
significance level of p<0.05 assumed.
Results
Systematic review
The literature search initially identified 954 possible relevant paper based on their titles. From these we identified
128 abstracts which appeared to fulfil the appropriate criteria, 39 of which were worthy of full text review. Only
15 reports examined predictive factors for orthopaedic intervention in 17 RA cohorts, 4 inception, 5 prospective
and 6 retrospective. 5 were not included because although all were reviews of orthopaedic outcomes in RA, they
did not in fact report on predictive factors. There was considerable variation in study recruitment decades and
cohort designs, especially in length of follow up and time to surgical intervention from onset of RA. Most reports
distinguished between all surgical interventions and TJR, only a few reporting on differences between specific
types of surgery. Although there was some variation in the parameters examined for predictive value, most
reports included clinical measures of joint disease activity (joint scores, DAS), laboratory acute phase (ESR,
CRP), RF and x-ray scores. Some included socio economic and functional measures (e.g. HAQ),
HAEMOGLOBIN and genotyping (HLA DR4 & SE). Acute phase, x-ray scores, women and HLA SE were the
most commonly reported prognostic markers, RF cited only uncommonly. The 15 reports are summarised in
Appendix 1, Table A.1.
Predictive analysis of UK datasets.
During the 25-year observation period, 711 patients from a total of 2701 had undergone at least one type of
orthopaedic intervention (n=1602, 25-year cumulative incidence (CI) 26.4%). The 25-year CI, adjusted for death as
competing risk, for any major intervention was 22% (95%CI 19–24) and for any intermediate interventions was
622% (95%CI 18–26) (Figure 1). The different types and frequency of orthopaedic interventions and a summary of
baseline and 1-year characteristics of patients having surgery are are shown in Appendix 1, Tables A.2 and A.3.
Competing risk regression analysis (Table 1) showed that the risk of both major and intermediate surgeries was
reduced in more recent study recruitment years by 6% (SHR 0.94, 95%CI 0.90-0.98) and 7% (SHR 0.93, 95%CI
0.88-0.98) respectively. Older age at disease onset predicted major intervention (SHR 1.01) and female gender more
than doubled the risk for intermediate surgery compared to males (SHR 2.11), although not for major surgery. Lower
BMI and haemoglobin predicted intermediate surgery in both baseline and 1-year models. Higher VAS or lower
ESR at baseline, or higher HAQ or TJC at 1-year, each predicted intermediate surgery. The higher the haemoglobin,
or lower the HAQ at 1-year, the lower the risk of major surgery. Higher HAQ at 1-year (Table 1) was associated
with >30% increased risk of major surgery. Whereas increased baseline BMI reduced the risk of intermediate
surgery (SHR 0.93, [0.0-0.96]), it predicted higher risk of major surgery (SHR 1.03, [1.01-1.06]). Erosions in
hands/feet at either baseline or 1-year were predictive for major surgery, but only erosions at 1-year were predictive
for intermediate surgery (SHR 1.45, [1.06-1.98]). Higher baseline TJC carried an increased risk, whereas increased
SJC at 1-year reduced the risk of major surgery.
High TJC and low SJC might indicate abnormalities of central pain processing, rather than inflammatory disease
activity.[11] To explore this further, we examined additional statistical models in which the separate DAS
components were replaced by DAS and DAS-P. The results are summarised in Supplementary Data, Appendix 1.
Multiple intermediate and major orthopaedic interventions
Predictors of multiple surgeries (defined as two or more major or intermediate surgeries) using negative binomial
regression are shown in Supplementary Data, Appendix 1, Table A.4. Modelling multiple surgical outcomes per
patient yielded similar associations to those observed for single first events. Very similar ratios and significant levels
were seen for the same predictive variables. Sensitivity analysis on the small proportion of patients who had both
major and intermediate surgery showed no difference in effects between surgery types.
Discussion
In this systematic review most studies examining RA outcomes by 5 years reported orthopaedic intervention in
around 15%, increasing to around 25% in 20yr+ follow up cohorts. These figures were confirmed by our detailed
analysis of a large UK inception cohort. Orthopaedic surgery is an important means of assessing medium to long-
term outcomes in RA and is considered both a surrogate marker of joint damage [12] and provides data on
unsuccessful medical treatment in RA.[13] Covering both the pre and post-biologic eras, this systematic review
and the analysis of orthopaedic interventions in two well-established RA inception cohorts has found consistency
in certain predictive factors, and considerable variation in others.
Although few studies distinguished between types of interventions, most reported that women had a higher risk for
surgery. In our current analysis this was so for intermediate surgery only, suggesting either more severe disease in
women or different thresholds for surgery. Hand surgery in women might be work-related, as in
administrative/typing roles, fabrics, kitchen work, and is subject of another study currently being undertaken. Other
7possibilities include lower thresholds for surgery stemming from differences in psychological, pain, functional and
cosmetic perceptions.
Age was not a consistent marker although the predictive analysis found an increased risk of major surgery in patients
older at disease onset. Average age of RA onset has increased in recent decades, and later studies may reflect an
increased need for orthopaedic surgery. In the predictive analysis study recruitment year also had an effect, with
more recent years predicting lower risk of surgery, most likely reflecting the impact of improved management of
RA on outcome, as we have reported recently.[6]
There was fair consistency in the ability of certain clinical and laboratory measures at early stages of RA to predict
the eventual need for orthopaedic surgery, including mainly acute phase and radiographic damage. Some studies
reported that haemoglobin and genotyping had additional clinically useful predictive value. Some studies reported
variations in type of, and predictive power of clinical and laboratory parameters for different surgical interventions
suggesting specific contributions from different pathological and/or patient-level factors. Attention to non-
inflammatory factors in addition to suppression of inflammation may be needed to minimise the burden of
orthopaedic surgery.
One quarter of patients presenting with RA underwent major or intermediate orthopaedic surgery during the
following 25 years. We have demonstrated that baseline and 1-year clinical and laboratory variables have clinically
useful and independent predictive value for eventual orthopaedic surgery. Similar risk factors for joint destruction
as measured on X-ray have been identified, mainly standard measures of active disease.[1-3] However, some
unexpected findings have emerged.
Early radiographic damage and low haemoglobin predicted both intermediate and major surgery, whereas variations
in predictive power of other parameters for the different surgical interventions suggest specific contributions from
different pathological and/or patient-level factors. Erosions at 1-year were predictive for both major and
intermediate surgery, although at baseline they were only predictive for major surgery. Baseline variables including
erosions are pre-DMARD therapy in these cohorts, and might not adequately reflect potential response to treatment.
Joint damage at 1-year reflects suboptimal response to treatment. Patients with progressive damage despite exposure
to treatment are more likely to require subsequent orthopaedic surgery than those in whom therapy has retarded
progression. 1-year measurements may therefore be better predictors of long term outcomes in RA than baseline,
prior to effective treatment.[6,7] The sub-analysis of Larsen scores in ERAS supports this, showing stronger
predictive value of Larsen at 1-year (p<0.001) compared to baseline (p<0.05). A similar explanation could apply
for prediction of major and intermediate surgery by HAQ at 1-year only. Prompt and intensive treatment of patients
with early RA might be expected to not only improve outcomes, but also permit earlier more accurate prediction of
surgical outcomes.
One of the most striking findings in our current analysis was the predictive value of haemoglobin for both major
and intermediate surgery, independent of other variables of active disease, the predictive effect being strongest with
haemoglobin at 1-year for major surgery. Our findings support the two previous reports that haemoglobin predicts
orthopaedic intervention, during the first 5 years after diagnosis [5], and over 25 years follow up in established
8arthritis.[13] It is well established that low haemoglobin is a marker of inflammatory disease activity. People with
RA display a blunted response to erythropoietin,[14] erythropoietin treatment has been associated with a reduction
in inflammatory activity,[15,16] and effective suppression of inflammation is associated with increases in
haemoglobin, suggesting a tight coupling between inflammatory activity and haematopoiesis. Iron metabolism
might, in addition, be directly involved in joint damage in RA. Higher iron deposition and iron-complexes in
synovial fluid and membranes have been associated with decreases in peripheral blood haemoglobin levels during
active RA[17] and iron deposition is associated with accelerated joint damage in haemochromatosis.
Although associations with active inflammation may contribute to the overall predictive power of haemoglobin for
orthopaedic surgery in RA, another report[18] supports our findings that anaemia-related progression of joint
damage might not be restricted to patients with clinically active disease. Non-inflammatory mechanisms might also
mediate associations between low haemoglobin and subsequent orthopaedic surgery. Low haemoglobin may also
be related to chronic NSAID use, which has been associated with increased joint damage.[19-21] Unfortunately,
data on cumulative NSAID use were not available for our cohorts. Whatever the underlying mechanism, our data
support the inclusion of haemoglobin in predictive models for joint surgery, in addition to standard measures of
inflammation.
We found that different DAS components had opposing predictive values for subsequent orthopaedic surgery, a
possible explanation for the weak predictive value of total DAS. Higher TJC at baseline and 1-year had positive
predictive value for intermediate joint surgery. SJC at 1-year had the opposite effect, reducing the risk of major
surgery. These findings suggest that patient-reported symptoms (pain and tenderness), might be stronger drivers for
joint surgery, whereas high objective measures of synovitis might result in surgery being postponed or averted while
further attempts are made to suppress inflammatory disease activity. Consistent with this, we found that DAS-P (but
not DAS) had positive predictive value for intermediate surgery.
Associations between clinical inflammation and joint damage in RA are often weak and inconsistent,[22-24] in part
due to the limited sensitivity and specificity of clinically detected synovitis to predict the presence or activity of
synovial pannus.[25] Clinical measurement of disease activity usually depends on composite scores such as DAS,
which combine patient-reported (VAS and TJC), physician observed (SJC) and laboratory (ESR or CRP)
components. Although each of these components increases with increasing inflammatory activity in RA, individual
components may reflect different underlying pathological mechanisms. In particular, it has been proposed that VAS
and TJC, or the proportion of DAS attributable to these components (DAS-P) might be more influenced by central
pain mechanisms, whereas SJC and ESR might be more directly associated with inflammatory disease activity.[26]
Discrepancies in predictive values of joint scores for hand/foot versus major joint replacement surgery could be due
to a number of other factors: higher joint scores can be achieved in hands and feet compared to large joints, in which
synovitis maybe less easy to detect; not all joints are included in DAS (e.g. hips); the more demanding nature of
major joint surgery can lead to higher thresholds for intervention, not necessarily driven by patient symptoms; higher
SJC may lower thresholds for more intensive medical therapies.
9Despite an apparently protective effect of high BMI on intermediate surgery, high BMI predicted increased
likelihood of major orthopaedic surgery. The influence of BMI on disease activity in RA is unclear. Some studies
have shown protective effects of higher BMI, with lower BMI associated with higher disease activity,[27] increased
erosions, more severe systemic RA (cachexia) and reduced survival.[28,29] Other studies have shown obesity an
independent risk factor for impaired quality of life in RA and poor disease outcomes.[30]
A strong link between obesity and knee osteoarthritis is well-recognised,[31] although reports on the predictive
value of high BMI for large joint surgery vary for OA [32] and RA.[33] High BMI may increase loading on already
compromised joints, and be associated with OA through genetic or metabolic mechanisms.[34] Such mechanisms
may be discrete from those leading to intermediate orthopaedic surgery.
Our current study complements existing data as identified through our literature search. Strengths of our current
predictive analysis include the “real life” setting of ERAS and ERAN, reflecting the therapeutic practices of both
pre and post-biologics treatment decades; length of study follow up; low attrition rates for orthopaedic data through
HES; and corroboration and extension of source data by linkage to national datasets. The use of modern statistical
techniques, in particular competing risk regression, has enabled maximum use of data and accounted for both the
event of interest (orthopaedic surgery) as well as death allowing for more precise estimates of the effects of
independent variables.
Although our observational study design allows identification of associations between baseline variables and
orthopaedic interventions, defining causal factors is not possible, especially in the absence of a control group, or
placebo-controlled interventions. As allocation of treatment in our study was not randomized, it is possible that the
resulting imbalance in underlying risk profiles could introduce bias (confounding by indication).[35] Lack of
treatment randomisation precluded adequate investigation of possible effects of steroids and DMARDs on surgical
rates, unavoidable in observational studies [6,36], but the presence of widely adopted UK treatment guidelines and
the examination of baseline and 1-year variables only should minimise this bias.
Another potential limitation is case definition, i.e. what is considered “RA-related” joint surgery, since coincidental
pathophysiological processes, including osteoarthritis and fracture, might have been the main triggers for
orthopaedic intervention. Separate analysis of RA-related and unrelated orthopaedic procedures is not possible, due
to difficulties with case definition, and potential interactions. RA patients who undergo TKR surgery usually display
osteophytes on plain radiographs, but also display more intense synovitis than those undergoing surgery for OA
alone.[37] There are currently no definitive classification criteria that permit valid discrimination between OA
secondary to RA and comorbid primary OA. Indeed, even in those with primary OA, comorbid inflammatory
synovitis might increase rates of structural progression and hasten the need for major joint surgery.[38] Patients
with RA, by merit of already being under specialist care, might have facilitated access to orthopaedic surgery even
for comorbid conditions.
Generalising our findings to other healthcare systems requires caution, although they have been enhanced by data
collection within a nationalised (UK) health service, with extensive linkage to national databases. Finally, we cannot
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exclude other possible important contributions to prediction of orthopaedic surgery from factors not measured in
our cohorts. Future studies should also examine both the cumulative effects of disease markers over time, and also
possible associations between orthopaedic intervention and patient-centred outcomes such as work disability.
Conclusions
This report provides information that could be use for planning future healthcare provision of orthopaedic surgery,
in light of the changing prevalence and characteristics of early RA, increasing prevalence of obesity, and an ageing
population. Our findings point to multiple and complex mediators of future orthopaedic surgery in people presenting
with RA, suggesting that interventions additional to the control of inflammatory disease may be important in
minimising the burden of orthopaedic surgery for patients and health care systems in the future. Predicting even
late joint destruction and need for surgery up to 25 years later is possible and more accurate at one year of therapy,
rather than at the time of RA diagnosis. EULAR recommendations[39] emphasize the importance of early
intervention with DMARDs followed by biologics if response is insufficient. Most of the predictive factors
identified through previous studies as well as current analysis are potentially reversible with appropriate therapy. It
is postulated that stratifying therapies based on these prognostic factors measured at 1-year could further reduce the
structural damage that leads to orthopaedic intervention up to 25 years later.
Abbreviation List
anti-TNFa anti-Tumour Necrosis Factor alpha
BMI Body Mass Index
CI Confidence Interval
CRP C-Reactive Protein
DAS Disease Activity Score
DAS-P Disease Activity Score (patient-reported components)
DMARD Disease-Modifying Anti-Rheumatic Drug
ERAN Early Rheumatoid Arthritis Network
ERAS Early Rheumatoid Arthritis Study
ESR Erythrocyte Sedimentation Rate
EULAR European League Against Rheumatism
Fe Iron
HAQ Health Assessment Questionnaire
HES Hospital Episode Statistics
HR Hazard Ratio
IRR Incidence Rate Ratio
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NHS National Health Service
MRIS Medical Research Information Service
NICE National Institute for Health and Care Excellence
NJR National Joint Registry
NSAID Non-Steroidal Anti-Inflammatory Drug
RA Rheumatoid Arthritis
SHR Sub-Hazard Ratios
SCQM Swiss Clinical Quality Management
THR Total Hip Replacements
TJR Total Joint Replacements
TKR Total Knee Replacement
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Figure 1. Cumulative incidence plots for each type of surgery.
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Table 1: Major and intermediate interventions. Competing-risks Multivariate Predictive Model.
*P<0.05 **P<0.01 ***P<0.001.
Intermediate Interventions Major Interventions Total Hip Only Total Knee Only
Variable SHR Wald 95% CI SHR Wald 95% CI SHR Wald 95% CI SHR Wald 95% CI
Baseline
Model
Gender 2.13*** 3.72 1.43,3.17 1.00 0.02 0.76,1.33 1.03 0.15 0.70,1.51 1.04 0.21 0.71,1.54
Age at Onset 1.00 -0.90 0.99,1.01 1.01** 3.00 1.00,1.02 1.02*** 3.35 1.01,1.04 1.01 1.51 1.00,1.02
Recruitment Yr 0.95*** -3.38 0.92,0.98 0.94*** -4.26 0.92,0.97 0.95* -2.55 0.92,0.99 0.92*** -4.00 0.88,0.96
Diagnosis time 1.00 -0.42 0.98,1.02 1.00 -0.28 0.98,1.01 1.00 -0.30 0.97,1.02 1.00 -0.02 0.98,1.02
BMI 0.94*** -4.31 0.91,0.96 1.03* 2.52 1.01,1.06 1.02 0.90 0.98,1.05 1.08*** 4.79 1.04,1.11
Erosions 1.35 1.94 1.00,1.84 1.39* 2.33 1.05,1.82 1.22 1.00 0.82,1.81 1.22 1.03 0.84,1.77
Rheum Factor 1.17 1.07 0.88,1.57 0.86 -1.14 0.67,1.11 1.02 0.08 0.71,1.45 0.83 -1.07 0.59,1.17
SJC 0.99 -0.67 0.97,1.01 0.98 -1.92 0.96,1.00 0.98 -1.36 0.96,1.01 0.98 -1.56 0.95,1.01
TJC 1.03* 2.09 1.00,1.05 1.02 1.87 1.00,1.04 1.03* 2.04 1.00.1.06 1.01 0.58 0.98,1.03
ESR .099* -2.20 0.99,1.00 1.00 1.27 1.00,1.01 1.00 0.75 1.00,1.01 1.00 1.24 1.00,1.01
HAQ 1.01 0.10 0.80,1.28 1.11 1.07 0.91,1.36 1.00 0.02 0.77,1.31 1.25 1.71 0.97,1.62
Haemoglobin 0.88* -2.39 0.79,0.98 0.85** -3.09 0.77,0.94 0.88* -2.00 0.77,1.00 0.87* -2.00 0.76,1.00
1 – Year
Model
Gender 1.79** 2.74 1.18,2.71 0.82 -1.26 0.61,1.11 0.82 -0.91 0.53,1.26 0.88 -0.64 0.59,1.30
Age at Onset 0.99 -1.56 0.98,1.00 1.01* 2.58 1.00,1.02 1.02** 3.09 1.01,1.04 1.01 1.08 0.99,1.02
Recruitment Yr 0.94** -3.12 0.91,0.98 0.95** -3.23 0.93,0.98 0.97 -1.82 0.93,1.00 0.93*** -3.31 0.88,0.97
Diagnosis time 0.99 -1.07 0.96,1.01 0.99 -1.09 0.97,1.01 0.99 -0.54 0.97,1.02 0.98 -1.06 0.96,1.01
BMI 0.93*** -4.35 0.90.0.96 1.03* 2.24 1.00,1.06 1.02 1.03 0.98,1.06 1.07*** 4.25 1.04,1.10
Erosions 1.51* 2.53 1.10,2.08 1.34* 2.00 1.01,1.78 1.15 0.66 0.76,1.72 1.24 1.08 0.84,1.82
Rheum Factor 1.1 0.62 0.81,1.51 0.84 -1.26 0.65,1.10 1.04 0.19 0.71,1.52 0.8 -1.27 0.56,1.13
SJC 0.98 -1.56 0.95,1.01 0.97** -2.85 0.95,0.99 0.97 -1.81 0.94,1.00 0.98 -1.78 0.95,1.00
TJC 1.03* 2.03 1.00,1.07 1.02 1.74 1.00,1.05 1.04* 1.97 1.00,1.08 1.00 0.06 0.97,1.04
ESR 1.00 -1.28 0.99.1.00 1.00 1.24 1.00,1.01 1.00 0.87 1.00,1.01 1.00 0.23 0.99,1.01
HAQ 1.28 1.91 0.99,1.66 1.40*** 3.36 1.15,1.71 1.29 1.92 0.99,1.68 1.43** 2.72 1.10,1.84
Haemoglobin 0.85** -2.72 0.75,0.95 0.81*** -4.24 0.73,0.89 0.81** -2.85 0.70,0.94 0.83** -2.95 0.73,0.94
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SUPPLEMENTARY MATERIAL
Appendix 1
Statistical details for observational data analysis
The following were entered into the model as core covariates of interest, given their importance in RA: gender, age at disease-onset, recruitment year, time to diagnosis at
baseline, rheumatoid factor (RF), BMI, HAQ, disease activity score (DAS) based on the original DAS (ERAS) and modified DAS28 (ERAN),[10] and its individual components
including tender (TJC) and swollen joint counts (SJC), patient-reported visual analogue scale (VAS), haemoglobin, ESR, hands and feet x-rays assessed for erosions by each
centre (Larsen scores were available in a subgroup of 70% of ERAS patients as previously described).[3] As baseline and 1-year variables did not differ significantly in these
patients (data not shown), sub group analysis included Larsen scores.
In order to establish other covariates to include in the model, univariate analysis was undertaken (results not shown). Those significant to p<0.01 were also included. In further
models, DAS and the proportion of DAS attributable to patient-reported components (TJC and VAS) termed DAS-P were also examined.[11] DAS and DAS-P were only
weakly correlated (r<0.50), so were included together. Overall missing baseline data were infrequent (around 5%), unlikely to introduce bias. Sensitivity analysis was performed
to test robustness of multivariate models by excluding variables with missing data both separately and together in the models (see supplementary material). To assess variance
and predictive strength of the regression models, the pseudo R2 and Area Under the Curve (AUC) were examined for baseline and 1-year models. Those variables with 10 year
follow-up were entered as time-varying covariates (TVC), where missing data were imputed using multiple imputation techniques to test the assumption of proportionality over
time. Finally, to investigate predictors of multiple surgeries, negative binomial regression was used on the total major or intermediate interventions. All analysis was conducted
using Stata (version 13) with significance level of p<0.05 assumed.
Appendix 1
Analysis of DAS-P - results
In these models, baseline DAS-P predicted intermediate surgery (35% increase risk), but not major surgery (Appendix I). The associations between surgery and other baseline
or 1-year variables were otherwise similar to those identified in the models that used individual DAS components (Appendix I).
20
For both major and intermediate surgery models, using either DAS components or DAS/DAS-P, the pseudo R2 was 0.34 for each baseline model, and 0.41 for each 1-year
model, suggesting that the models explain 34% and 41% of the total variance respectively. Predictive accuracy measured by AUC of baseline/1-year models was 76/74% for
intermediate and 72/63% for major surgery in both the DAS component models and the DAS/DAS-P models. Entering 10-year follow-up data as a TVC in the model revealed
no significant interaction between any of the covariates and time, indicating that the effect was proportional over time.
A sub-analysis in ERAS using Larsen scores showed that baseline scores predicted major surgery (SHR 1.02, [1.00-1.03]). 1-year Larsen scores had predictive power (p<0.001)
for both intermediate and major surgery, an increased risk of 3% for every unit increase in Larsen score. The variables with highest missing data used in the regression models
were baseline BMI (13%) and 1-year haemoglobin (8%) and HAQ (9%). Sensitivity analyses indicated that missing data made little difference to the overall results (see
supplementary material). Comorbid osteoarthritis (OA) was recorded in ERAS as previously described.[6] Sensitivity analysis excluding these patients undergoing major joint
replacement surgery (5.2%) made no difference to effect estimates, suggesting that these did not bias the main analysis.
Table A.1 Summary of reports fulfilling the inclusion criteria for the review. Where more than one report has been derived from the same cohort, these have been
identified by *, + or §
Authors/dates/centre Study type, sample size, FUp N/% Orth Surg & TJR Predictive factors & analysis type: Uni/multivariate Cox, Log R
Reilly PA 1990 UK.
Unicentre
Inception n=110, 35 survivors at
25yrs
OS=22 (72%) Predictor
variables: age/sex, FG
OS Risk: F, FGrade
Eberhardt 1996 Sweden
Unicentre *
Inception cohort,2 &5yr FUp n=99 TJR=15 (15%) Predictor
variables: HLA SE
OS Risk: HLA SE not related to OS
Kuper 1997
Unicentre Netherlands
Prospective 6yr FUp x-ray scores
large joints n=157
OS = 22 (large joints) None for surgery, mainly X-ray damage large joints
Wolfe F & Zwillich 1998.
US Unicentre
Prospective observational 1974-
1997 n=1600 23yr FUp
OS=541 (34%) TJR= 36.5%
Predictor variables n=14
TJR Risk (UCox): Very high HAQ & high ESR=x3-6
Others: Pain VAS, erosions, Hb, WCC. Smoking protective. RF: NS
Weyand 1998. US
1 county
Retrospective 1970-1985 10yrFUp
n=165
OS=67(ops=133) Predictor
variables: age/sex
Hand/wrist OS Risk: F (55% v27%) F
Crilly 1999
Unicentre UK
Case control n=65 TJR 15yr FUp OS=65 TJR risk: HLA DRb1 homozygous = x5 risk OS
risk: high ESR , HAQ slight increase
Young 2000 UK +
Multicentre
Inception cohort 1986-1998
5yrFUp n=732
OS=117(17%) TJR=55 (8%)
Predictor variables n=14
OS risk: Older age & HAQ – NS trends only
Massardo L 2002 US §
Population based
Retrospective 1955-1985 n=424
median 14yrs FUp
OS=148 (35%) TJR=76
Predictor variables:
OS risk (UCox): high: youth & nodules low: F & RF+
Da Silva 2003 US §
Population based
Retrospective 1955-1995 n=609
FUp 30yr
OS=242 (40%) TJR=85 (%)
Predictor variables:
OS risk(U& MCox): F, youth, RF, nodules
21
James D 2004. UK +
Multicentre
Inception cohort 1986-2002
5yrFUp n=1064
OS=181 (17%) TJR=75(7%)
Predictor variables n=14
TJR risk: Hb, ESR, DAS, x-ray scores. Hand/foot risk: F, x-ray score,
HAQ. All OS: HLA SE LogR: ESR, DAS, HAQ, HLA SE
Lindqvist E 2002 Sweden *
Unicentre
Prospective 1985-2000 n=168 10yr
FUp
OS=30 (17% all TJR)
Predictor variables:
OS risk (LogR): Age, M, HLA SE, RF, HAQ, ESR, SJC
Kapetanovic MC 2008 *
Sweden Unicentre
Prospective 1985-2005 n=113 16-
20yr FUp
OS=106 (58%) TJR=44(24%)
Predictor variables:
OS risk (UniV): x-ray score, HAQ, CRP, Rx, HLA SE
Cox: HAQ, CRP/ESR, x-rays
Shourt CA 2012 US §
Population based
Retrospective 1980-2007 n=813
FUp 9.6yrs(mean)
OS=189 (%)Predictor
variables:
OS risk: F TJR: F, BMI (obese) Minor surgery: smokers
Gossec L France 2004 Retrospective n=300 FUp 12yr OS=24% TJR=13% OS: HLA SE not predictive
Verstappen S 2006
Netherlands Unicentre
1990-98 FUp 2-14yrs Early v
delayed Rx clinical trial n=482
(mean FUp 7.2yrs)
OS=130 (27%) TJR=10%
Predictor variables n=8
OS (UCox): JSc, ESR. Pain, HAQ, x-ray scores, response to Rx, early Rx.
Not age, sex, RF, EMS
MCox: early Rx,, x-ray scores
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Eberhardt KB, Fex E, Johnson U, Wollheim FA. Association of HLA-DR_ and DQ_ genes with two and five year outcome in rheumatoid arthritis. Ann Rheum Dis 1996;55:34–9.
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Table A.2. Number and type of orthopaedic interventions by category over the 25 years of study follow-up.
Type of procedure Number of episodes (n) Incidence Rate per
1000
95% CI
TJRs 562 18.2 16.7-19.8
THRs 221 7.2 6.3-8.2
TKRs 277 9.0 8.0-10.1
Other 64 2.1 1.6-2.6
Cervical spine 9 0.3 0.1-0.6
Large joint # 71 2.3 1.8-2.9
All Intermediate 383 12.4 11.2-13.7
Intermediate for # 14 0.5 0.2-0.8
All Minor 527 17.1 15.7-18.6
Minor for # 27 0.9 0.6-1.3
Miscellaneous 50 1.6 1.2-2.1
Total 1602 51.9 49.5-54.4
TJRs=Total Joint Replacements, THRs=Total Hip Replacements, TKRs=Total Knee Replacements, #=fracture.
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Table A.3. Baseline and 1-year disease features, patient characteristics, length of follow up and treatments in the “no intervention”, “intermediate” and “major”
categories.
No
major/intermediate
Intervention
Intermediate Major Whole
Cohort
Variable (n=2173) (n=267) (n=341) (n=2701)
Age at disease-onset(yrs), mean ± SD 56.24 ± 14.6 52.5 ± 14.6 57.5 ± 12.7 56.1 ± 14.4
Women, n (%) 14-05 (64.6) 225 (84.3) 248 (72.7) 1812 (67.1)
Length of Follow-up (yrs), median
(IQR)
8 (12) 19 (9) 17 (11) 9 (13)
Rheumatoid Factor +ve, n (%) 1223 (61.7) 179 (65.6) 201 (60.2) 1553 (61.8)
Baseline BMI, mean ± SD 26.7 (5.1) 24.9 (4.0) 26.6 (4.9) 26.5 (5.0)
Baseline DAS, mean ± SD 4.7 ± 1.5 5.2 ± 1.2 5.2 ± 1.2 4.8 ± 1.4
Baseline HAQ, mean ± SD 1.1 ± 0.8 1.2 ± 0.8 1.3 ± 0.8 1.1 ± 0.8
Baseline Haemoglobin, mean ± SD 13.0 ± 1.5 12.3 ± 1.4 12.3 ± 1.6 12.8 ± 1.5
Baseline ESR, mean ± SD 35.8 ± 27.1 39.8 ± 26.9 46.9 ± 29.6 37.2 ± 27.5
Baseline erosions, n(%) 478(17.7) 61(2.2) 107(3.9) 646(23.9)
DMARD use by 3 years, n (%)
Monotherapy 692 (55.1) 95(49.7) 140(50.7) 927 (53.8)
Sequential Monotherapy 191(15.2) 41(21.5) 58(21.0) 290 (16.8)
DMARD Add-on/step-up* 220(17.5) 45(23.6) 57(20.7) 322 (18.7)
Combination 2 DMARD* 61(4.9) 6(3.1) 4(1.4) 71 (4.1)
Combination 3 DMARD* 25(2.0) 1(0.5) 2(0.7) 28 (1.6)
DMARDS + TNF 67(5.3) 3(1.6) 15(5.4) 85 (4.9)
Year 1 DAS, mean ± SD 3.8 ± 1.5 4.3 ± 1.6 4.4 ± 1.5 3.9 ± 1.6
Year 1 HAQ, mean ± SD 0.8 ± 0.8 1.0 ± 0.8 1.1 ± 0.8 0.9 ± 0.8
Year 1 Haemoglobin, mean ± SD 13.1 ± 1.5 12.3 ± 1.5 12.3 ± 1.4 12.9 ± 1.5
Year 1 ESR, mean ± SD 25.3 ± 23.0 31.5 ± 24.9 35.0 ± 26.0 26.9 ± 23.7
*DMARD add-on or step-up therapy refers to single DMARD addition to an existing DMARD sequentially over time, whereas combination 2 or 3 DMARD therapy refers to
starting 2 or 3 DMARDs at the same time or within a maximum of one month from each other. Missing baseline data: Rheumatoid factor (4%), DAS28 (2%), HAQ (1.6%),
Haemoglobin (1.4%), ESR (7%); BMI (13%). Missing 1-year data: DAS28 (12%), HAQ(19.9%), Haemoglobin (18.8%), ESR (24.4%).
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Table A.4: Prediction of Multiple Orthopaedic Interventions. Negative Binomial Regression Model.
Intermediate Interventions Major Interventions
Variable SHR Wald 95% CI SHR Wald 95% CI
Baseline
Model
Gender 2.09** 2.96 1.28,3.41 1.12 0.69 0.82,1.53
Age at Onset 0.97*** -5.95 0.96,0.98 1.00 0.43 0.99,1.01
Recruitment year 0.88*** -6.38 0.85,0.92 0.88*** -8.60 0.86,0.91
Time to Diagnosis 1.01 0.56 0.99,1.03 1.00 -0.33 0.98,1.02
BMI 0.96 -1.87 0.92,1.00 1.05** 3.23 1.02,1.07
Erosions 1.17 0.78 0.79,1.75 1.33 1.80 0.97,1.83
Rheumatoid Factor 1.29 1.32 0.88,1.88 0.86 -1.05 0.65,1.14
SJC 0.99 -0.48 0.97,1.02 0.99 -1.25 0.97,1.01
TJC 1.01 0.82 0.98,1.04 1.02 1.83 1.00,1.05
ESR 0.99** -2.62 0.98,1.00 1.00 1.01 1.00,1.01
VAS 1.01* 2.10 1.00,1.02 1.00 0.07 0.99,1.01
HAQ 0.88 -0.85 0.65,1.19 1.09 0.79 0.88,1.35
Haemoglobin 0.81** -2.81 0.70,0.94 0.86** -2.58 0.77,0.97
1-Year
Model
Gender 2.05** 2.86 1.25,3.35 1.02 0.14 0.74,1.42
Age at Onset 0.96*** -6.58 0.95,0.97 1.00 -0.45 0.99,1.01
Recruitment year 0.88*** -4.18 0.82,0.93 0.88*** -6.80 0.84,0.91
Time to Diagnosis 1.00 -0.22 0.97,1.03 0.98 -1.68 0.96,1.00
BMI 0.93** -3.01 0.89,0.97 1.04** 2.66 1.01,1.08
Erosions 1.10 0.48 0.75,1.60 1.44* 2.51 1.08,1.92
Rheumatoid Factor 1.09 0.44 0.74,1.60 0.79 -1.56 0.59,1.06
SJC 0.96* -2.28 0.94,0.99 0.96** -2.85 0.94,0.99
TJC 1.05* 2.20 1.01,1.09 1.03* 2.00 1.00,1.06
ESR 1.00 -1.09 0.99,1.00 1.00 0.36 0.99,1.01
VAS 1.00 -0.42 0.99,1.01 1.00 -0.57 0.99,1.00
HAQ 1.27 1.31 0.89,1.82 1.36* 2.37 1.05,1.75
Haemoglobin 0.83** -2.65 0.73,0.95 0.81*** -3.81 0.72,0.90
*P<0.05 **P<0.01 ***P<0.001
